Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene Therapies

3 Feb 2025

Abstract excerpt

This cross-sectional study compares how sponsors approach parallel submissions of gene and cell therapy applications to drug regulatory agencies.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomedical Ethics and Regulation
Share to Biotechnology and Related Fields

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39899303
DOI: 10.1001/jamainternmed.2024.7569

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of Clinical Evidence Submitted to the FDA and EMA for Cell and Gene TherapiesPMID 39899303Read ↗

Clinical development of gene- and cell-based therapies: overview of the European landscapeSemantic proximity Read ↗

Development of Cell and Gene Therapies for Clinical Use in the US and EU: Summary of Regulatory GuidelinesSemantic proximity Read ↗

23andMe and the FDA.Semantic proximity Read ↗

Long-term follow-up after authorization of gene therapy: leveraging real-world dataSemantic proximity Read ↗

A few ethical issues in translational research for gene and cell therapySemantic proximity Read ↗

Task Force on Strategic Research Direction: Clinical Science Subgroup key science topics report.Semantic proximity Read ↗

ISSCR’s Guidelines for Stem Cell Research and Clinical Translation: Supporting development of safe and efficacious stem cell-based interventionsSemantic proximity Read ↗

Deficiency Patterns in FDA Complete Response Letters for New Drug and Biologics Applications: A Cross-Sectional AnalysisSemantic proximity Read ↗

Considerations for Cell and Gene Therapy Programs Entering the Clinical SpaceSemantic proximity Read ↗

Real World Evidence – Current Developments and PerspectivesSemantic proximity Read ↗

The Current Landscape of Clinical TrialsSemantic proximity Read ↗

“A Process-Based Approach to Conflicts of Interest”Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.